00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
22:09 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Akers raises $6.9M in follow-on

Diagnostic company Akers Biosciences Inc. (NASDAQ:AKER; LSE:AKR) said on Dec. 21, 2017, it raised $6.9 million through the sale of 21.5 million class A units at $0.15 and 3,675 class B units at $1,000 in...
23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for...
21:06 , Apr 6, 2017 |  BC Week In Review  |  Financial News

Akers completes private placement

Diagnostic company Akers Biosciences Inc. (NASDAQ:AKER; LSE:AKR) raised $2 million through the sale of 1.4 million shares at $1.40 in a private placement on March 30. Investors also received five-year warrants to purchase up to...
16:16 , Jan 12, 2017 |  BC Week In Review  |  Financial News

Akers completes follow-on

Akers raised $2 million through the sale of 1.7 million shares at $1.20 in a follow-on underwritten by Joseph Gunnar. Investors also received five-year warrants to purchase up to 833,500 shares at $1.50. Akers Biosciences...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

PIFA Heparin/PF4 rapid assay regulatory update

The China Food and Drug Administration (CFDA) approved Akers’ PIFA Heparin/PF4 Rapid Assay to test for allergic reactions associated with heparin. The diagnostic test to detect heparin-induced thrombocytopenia (HIT) antibodies is approved in the U.S....
07:00 , Oct 23, 2014 |  BC Innovations  |  Cover Story

Diagnosing resistance

It might be a day late and a dollar short, but the U.S. government is finally getting around to addressing what many experts think is the big unserved need in antibiotic resistance-new diagnostics. Faster, more...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Akers Biosciences, Konica Minolta deal

Akers partnered with Konica Minolta to evaluate the feasibility of developing a rapid test for the early detection of cardiac muscle tissue damage based on Akers’ Particle Immuno Filtration Assay (PIFA) technology and seraSTAT rapid...
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

Akers Biosciences, Jai Capital deal

Akers granted Jai non-exclusive rights to commercialize four of Akers' rapid tests in India. The products are Akers' PIFA Heparin / PF4 test to detect heparin-induced thrombocytopenia (HIT) antibodies; PIFA Dengue Fever screening test for...
07:00 , May 12, 2014 |  BC Week In Review  |  Clinical News

PIFA PLUSS Chlamydia Assay: Clinical trial started

Akers began a U.S. clinical trial to evaluate its PIFA PLUSS Chlamydia Assay in 200-250 subjects, including healthy subjects; newly and actively infected chlamydia patients; and previously infected and treated chlamydia patients. Akers Biosciences Inc....